Newsroom Search Results
Coverage
Biden-Harris Administration Protects Consumers from Low-Quality Coverage by Limiting “Junk” Health Plans
These actions build on the Biden-Harris Administration’s effort to eliminate hidden fees and consumer traps in every sector of the economy.
CMS Statement on Current Status of Blood Tests for Organ Transplant Rejection
Statement: Patients with transplanted hearts, lungs, or kidneys who meet Medicare’s local coverage criteria can continue to access blood tests used to monitor for organ transplantation when ordered by their doctors. In March 2023, the Centers for Medicare & Medicaid Services’ (CMS), through its
CMS Provides Critical Tools to Help Improve Access for Millions who Receive Medicaid Home- and Community-based Services
New guidance outlines how states can establish important tools to connect individuals needing care with those qualified to provide it.The U.S. Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS), today took another critical step to improve access
HHS Takes Action to Provide 12 Months of Mandatory Continuous Coverage for Children in Medicaid and CHIP
Letter sent to state health officials in all 50 states, D.C., and US territories
CMS Statement on Current Status of Blood Tests for Organ Transplant Rejection
Important: On 2/29/2024 CMS issued an updated statement on this issue. For more information go here.The Centers for Medicare & Medicaid Services (CMS) confirms that neither CMS nor the Medicare Administrative Contractors (MACs) have made changes that affect patients’ ability to have blood tests used
Short-Term, Limited-Duration Insurance; Independent, Noncoordinated Excepted Benefits Coverage; Level-Funded Plan Arrangements; and Tax Treatment of Certain Accident and Health Insurance (CMS-9904-P)
On July 7, 2023, the Department of Health and Human Services (HHS), the Department of Labor, and the Department of the Treasury (collectively, the Departments) released a notice of proposed rulemaking (NPRM). This NPRM proposes to modify the definition of short-term, limited-duration insurance
Statement: Broader Medicare Coverage of Leqembi Available Following FDA Traditional Approval
Broader Medicare coverage is now available for Biogen and Eisai’s Leqembi (the brand name for lecanemab) following the Food and Drug Administration’s (FDA) move to grant traditional approval to the drug that treats individuals with Alzheimer’s disease. The Centers for Medicare & Medicaid Services
Notice with Comment - Transitional Coverage for Emerging Technologies (CMS-3421-NC)
The Centers for Medicare & Medicaid Services (CMS) issued a proposed procedural notice outlining a new Medicare coverage pathway to achieve more timely and predictable access to new medical technologies for people with Medicare. The new Transitional Coverage for Emerging Technologies (TCET) pathway
CMS announces new details of plan to cover new Alzheimer’s drugs
The Centers for Medicare & Medicaid Services (CMS) is releasing new details about how people can get drugs that may slow the progression of Alzheimer’s disease covered by Medicare. If the Food and Drug Administration (FDA) grants traditional approval, then Medicare will cover the drug in appropriate
HHS Takes Additional Action to Keep People Covered as States Resume Medicaid, CHIP Renewals
In a letter to the nation's governors, Secretary Becerra announces new flexibilities HHS is offering states to minimize avoidable coverage losses among children and families.